Gilead SUPHO01-ENHANCEIII AML
- Working group party:
- 1st lijn
- Level C-HIC&C-SCT
- Included patients:
- Active sites:
18(of 19)4 sites are pending
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Safety and Efficacy of Magrolimab versus Placebo in
Combination with Venetoclax and Azacitidine in Newly Diagnosed,
Previously Untreated Patients with Acute Myeloid Leukemia Who Are
Ineligible for Intensive Chemotherapy
01FEB2023: Europe screening and enrollment is re-open again.
HOVON is giving support to GILEAD for the conduct of the SUPHO01-ENHANCE III study.
The trial management will be performed by ICON.
However, if you have questions f.i. for the coordinating HOVON investigator G. Huls (UMCG) please contact us.
- Prospective double-blind randomized phase III study
- Monitoring Type:
- Study Specific